{"version":"1.0","provider_name":"Tehnopol Science and Business Park","provider_url":"https:\/\/www.tehnopol.ee\/en\/","author_name":"Gerli Aarma","author_url":"https:\/\/www.tehnopol.ee\/en\/author\/gerli-aarma\/","title":"Chemestmed O\u00dc","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"vu6nrxNMX8\"><a href=\"https:\/\/www.tehnopol.ee\/en\/business-services\/health-tech-community\/members-partners\/chemestmed-ou\">Chemestmed O\u00dc<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.tehnopol.ee\/en\/business-services\/health-tech-community\/members-partners\/chemestmed-ou\/embed\/#?secret=vu6nrxNMX8\" width=\"600\" height=\"338\" title=\"&#8220;Chemestmed O\u00dc&#8221; &#8212; Tehnopol Science and Business Park\" data-secret=\"vu6nrxNMX8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.tehnopol.ee\/wp-content\/uploads\/2025\/09\/Koduka-moodus-pildid-11.jpg","thumbnail_width":1920,"thumbnail_height":1080,"description":"Chemestmed arendab esimesena maailmas sihip\u00e4raseid v\u00e4ikemolekulilisi ravimeid, mis parandavad RNA met\u00fclatsiooni. Me avastasime aastal 2019 \u00fchendid, mis t\u00f5stavad keemiliselt met\u00fc\u00fcltransferaasi METTL3 aktiivsust, parandades seel\u00e4bi mRNA met\u00fclatsiooni. See on uudne ja alauuritud mehhanismi, mille roll metaboolsetes ja neurodegeneratiivsetes haigustes on \u00fcha enam esile kerkimas. Meie platvormip\u00f5hine l\u00e4henemine \u00fchendab tipptasemel keemia, molekulaarbioloogia ja AI-p\u00f5hise ravimite disaini, et pakkuda uusi raviv\u00f5imalusi haigustele, millele praegu puuduvad t\u00f5husad lahendused."}